Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01011075 · ClinicalTrials.gov registry record · Phase 2
Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer
A Phase 2 study, sponsored by New Mexico Cancer Research Alliance.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT01011075 is a Phase 2 study that has completed, run by New Mexico Cancer Research Alliance. The registered enrollment target is 34 participants.
The verdict
NCT01011075, a Phase 2 study, has completed, sponsored by New Mexico Cancer Research Alliance.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
This study will evaluate the clinical efficacy of combining Gleevec (imatinib mesylate), a PDGFR antagonist, with front-line, single-agent paclitaxel in a cohort of elderly patients with advanced, non-small cell lung cancer.
Interventions
- DRUG Paclitaxel
- DRUG Imatinib mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2009-08 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01011075
The ClinicalTrials.gov registry entry for NCT01011075 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Mexico Cancer Research Alliance, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel is the first listed.
NCT01011075 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01011075 about?
NCT01011075 is a clinical study titled "Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer". This study will evaluate the clinical efficacy of combining Gleevec (imatinib mesylate), a PDGFR antagonist, with front-line, single-agent paclitaxel in a cohort of elderly patients with advanced, non-small cell lung cancer.
What is the current status of trial NCT01011075?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2009-08. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01011075?
The interventions under investigation include: Paclitaxel (DRUG), Imatinib mesylate (DRUG).
Who is sponsoring clinical trial NCT01011075?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.